Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced a definitive agreement to acquire Emalex Biosciences for $700 million in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Mergers and Acquisitions